No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy.
about
GLI1-mediated regulation of side population is responsible for drug resistance in gastric cancerDrugs, cancer and end-of-life care: a case study of pharmaceuticalization?Comparative analysis of the efficacy and safety of modified FOLFOX-6 and DCF regimens as first-line treatment in advanced gastric cancer.Identifying therapeutic targets in gastric cancer: the current status and future directionMetastatic spread in patients with gastric cancer.Targeting metastasis.Doctors' reports about palliative systemic treatment: A medical record study.Ten weeks to live: a population-based study on treatment and survival of patients with metastatic pancreatic cancer in the south of the Netherlands.Effect of age on rates of palliative surgery and chemotherapy use in patients with locally advanced or metastatic gastric cancer.Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy.[Rare cause of rectal stenosis].The role of GLI2-ABCG2 signaling axis for 5Fu resistance in gastric cancer.Improvement in survival for patients with synchronous metastatic esophageal cancer in the south of the Netherlands from 1994 to 2013.Identification of ARL4C as a Peritoneal Dissemination-Associated Gene and Its Clinical Significance in Gastric Cancer.
P2860
Q33689071-57D5666A-A3C6-4548-86C1-B01ADE73BE43Q35223735-4291C77A-84FA-4276-A2B5-8B48C532FEA4Q35948108-0C48E830-F68E-4180-9828-8AFF67F4E174Q36398732-D188536E-D421-4732-B0FB-AABAA35766F8Q37588449-90653B62-2AFE-4BBC-A741-A0121CE99A78Q38786658-2674C5DB-F5C8-404B-89B2-300FC693DE69Q38834421-FF878CC1-D242-40C7-ACB0-8A934768E5FEQ39121995-AC44E2A3-F074-485C-A6B4-4C76318523F7Q48269126-BFD9E0E6-EF31-4ADE-A181-2256D8971830Q48544302-7E369B2F-3AFF-456D-95B1-F16CC9A40798Q49630835-7335A3DA-6866-4903-9A60-9F5B36ECBFD4Q53093918-82FCDD42-6C29-440C-A1FA-FC14F416A434Q53101919-42DD7D32-073E-4789-96C9-07022BCA0B04Q54100467-D8E9E0B0-6657-48C4-94DC-F5D952A27DD6
P2860
No improvement in median survival for patients with metastatic gastric cancer despite increased use of chemotherapy.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
No improvement in median survi ...... increased use of chemotherapy.
@en
No improvement in median survi ...... increased use of chemotherapy.
@nl
type
label
No improvement in median survi ...... increased use of chemotherapy.
@en
No improvement in median survi ...... increased use of chemotherapy.
@nl
prefLabel
No improvement in median survi ...... increased use of chemotherapy.
@en
No improvement in median survi ...... increased use of chemotherapy.
@nl
P2093
P2860
P356
P1433
P1476
No improvement in median survi ...... increased use of chemotherapy.
@en
P2093
G A P Nieuwenhuijzen
G J Creemers
J F M Pruijt
N Bernards
V E P P Lemmens
P2860
P304
P356
10.1093/ANNONC/MDT401
P577
2013-10-11T00:00:00Z